Home | Site Map | Contact Us |  Tell a Colleague | Print Page  
Valcyte valganciclovir HCI tablets Roche
About Roche Transplantation Research Resources for Professionals Prescribing Information Community Support Industry Events/News
Sign Up
Login Here
E-mail
Password
Forgot Password

Important Safety and Prescribing Information

CellCept Zenapax Valcyte Learn More about the TPPP

Indications 

Valcyte tablets are indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor CMV seropositive/recipient CMV seronegative [(D+/R-)]).4

Valcyte is not indicated for use in liver transplant patients.4

The safety and efficacy of Valcyte for the prevention of CMV disease in other solid organ transplant patients, such as lung transplant patients, have not been established.4

  Safety Information

Reference:

4Valcyte® [product information]. Nutley, NJ: Roche Laboratories Inc.; January 2006.

 

 

 

 

 
Privacy Statement  |  Legal Statement  |  Intended for U.S. Physician Audiences Only Copyright © 2006-2008 - Roche Laboratories Inc. All rights reserved.